University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator
07 nov. 2018 16h30 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, congratulates CureVac...
CureVac präsentiert vorläufige Daten seiner Phase-I-Studie mit dem RNA-basierten Wirkstoff CV8102 zur intratumoralen Anwendung auf der 33. Jahrestagung der Society for Immunotherapy of Cancer
07 nov. 2018 07h00 HE
|
CureVac AG
Die Daten umfassen CV8102 als Einzelwirkstoff und in Kombination mit einer Anti-PD1-Therapie TÜBINGEN, Deutschland / BOSTON, USA, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Das biopharmazeutische...
CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
07 nov. 2018 07h00 HE
|
CureVac AG
Data to be presented includes CV8102 as a single agent and in combination with anti-PD1 therapy TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated...
CureVac verkündet den Start einer klinischen Phase-I-Studie mit mRNA-basiertem Tollwutimpfstoff
23 oct. 2018 07h13 HE
|
CureVac AG
Studie soll erste Daten zur intramuskulären Anwendung des von CureVac neu entwickelten Impfstoffs am Menschen liefern TÜBINGEN, Deutschland / BOSTON, USA, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Das...
CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine
23 oct. 2018 07h00 HE
|
CureVac AG
Trial to provide first-in-human data for CureVac’s novel mRNA-based intramuscular rabies vaccine TÜBINGEN, Germany and BOSTON, Oct. 23, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated...
CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations
12 juin 2018 07h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, June 12, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the...
CureVac Announces New Management Structure
08 mai 2018 06h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, May 08, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that...